Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Trial, condition or NCT IDCountrySponsorPhaseStatusConditionReset

21 trials match this view; 15 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 1,094 across 21 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Export filtered registry facts · JSONInteractive world map Germany source-checked report

Recorded study-start years

201711

201933

202044

202111

202222

202333

202433

202544

Current indexed registry status

Completed1616

Recruiting33

Active, not recruiting11

Enrolling by invitation11

Reported research conditions

Healthy1212

Anxiety Disorders22

Palliative Care11

Pain11

Anxiety11

Depression11

Demoralization11

Psychological Distress11

Quality of Life11

Caregiver Burden11

Fear of Death11

Existential Distress11

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

21 matching registry records. Dates are registry milestones, not promised results announcements.
Trial	Sponsor and phase	Status	Enrollment	Start / primary completion / completion
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects NCT06884514 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2026-06-25	24 ACTUAL	2025-04-03 2026-05-13 2026-05-28
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study) NCT05883540 Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress	University Hospital, Basel, Switzerland PHASE2	Recruiting Registry updated 2026-04-29	60 ESTIMATED	2024-06-09 2027-09 2028-05
Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants NCT06180759 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2026-04-02	17 ACTUAL	2025-01-23 2025-09-29 2025-11-06
Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans NCT06081179 Healthy	University of Zurich PHASE1	Completed Registry updated 2025-11-19	122 ACTUAL	2023-10-24 2025-09-22 2025-09-22
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment NCT07164287 Major Depressive Disorder (MDD) · Anxiety Disorders · Substance Use Disorder (SUD) · PTSD - Post Traumatic Stress Disorder	University Hospital, Geneva Phase not reported	Active, not recruiting Registry updated 2025-10-02	376 ESTIMATED	2020-06-01 2025-04-30 2025-09-30
Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study) NCT06796361 Healthy	University Hospital, Basel, Switzerland PHASE1	Recruiting Registry updated 2025-05-28	16 ESTIMATED	2025-04-21 2026-08 2026-08
The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training NCT05570708 Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD	Felix Mueller NA	Enrolling by invitation Registry updated 2025-04-14	48 ESTIMATED	2022-10-25 2029-06-01 2029-06-01
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study). NCT05695495 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2025-04-11	36 ACTUAL	2024-06-12 2025-02-02 2025-03-04
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study) NCT06899334 Healthy	University Hospital, Basel, Switzerland PHASE1	Recruiting Registry updated 2025-03-27	24 ESTIMATED	2025-04-01 2026-08-01 2026-08-01
Molecular Imaging Study of Harmine/DMT: a Basic Research Approach NCT06252506 Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine	Insel Gruppe AG, University Hospital Bern PHASE1	Completed Registry updated 2025-03-19	17 ACTUAL	2024-01-22 2025-02-17 2025-03-05
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects NCT05523401 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2025-03-05	24 ACTUAL	2023-08-16 2024-10-20 2024-11-05
Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study NCT05384678 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2024-04-25	24 ACTUAL	2022-11-15 2024-03-08 2024-03-13
Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects NCT04227756 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2024-01-24	32 ACTUAL	2020-05-19 2022-09-02 2022-09-02
Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators NCT05780216 Healthy Participants	Milan Scheidegger EARLY_PHASE1	Completed Registry updated 2023-09-21	40 ACTUAL	2023-02-20 2023-08-05 2023-09-15
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder NCT04141501 Alcohol Use Disorder	University of Zurich PHASE2	Completed Registry updated 2023-09-21	37 ACTUAL	2020-06-08 2023-03-14 2023-09-14
Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness NCT04849013 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2023-03-29	16 ACTUAL	2021-08-11 2023-03-27 2023-03-27
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression NCT03715127 Depressive Disorder, Major	University of Zurich PHASE2	Completed Registry updated 2022-04-29	55 ACTUAL	2019-03-11 2021-10-12 2022-04-12
LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study NCT03153579 Patients · Anxiety Disorders	University Hospital, Basel, Switzerland PHASE2	Completed Registry updated 2021-12-22	46 ACTUAL	2017-06-23 2021-12-15 2021-12-15
Characterization of Altered Waking States of Consciousness in Healthy Humans NCT03853577 Altered Waking States of Consciousness in Healthy Humans	University of Zurich NA	Completed Registry updated 2021-04-29	25 ACTUAL	2020-07-08 2021-04-25 2021-04-25
Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects NCT03604744 Healthy	University Hospital, Basel, Switzerland EARLY_PHASE1	Completed Registry updated 2021-04-27	28 ACTUAL	2019-03-27 2021-04-10 2021-04-15
Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects NCT03912974 Healthy	University Hospital, Basel, Switzerland PHASE1	Completed Registry updated 2020-12-01	27 ACTUAL	2019-07-04 2020-11-26 2020-11-26

Reported research facilities

University Hospital BaselBasel, Canton of Basel-City, Switzerland

University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland

University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland

Spital Uster AG, Division of Internal MedicineUster, Switzerland

University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland

Clinical Pharmacology & Toxicology, University Hospital BaselBasel, Switzerland

Psychiatrische Universitätsklinik ZürichZurich, Switzerland

Geneva University HospitalGeneva, Switzerland

Clinical Trial UnitBasel, Canton of Basel-City, Switzerland

University HospitalBasel, Switzerland

Department of Nuclear Medicine, Bern University HospitalBern, Switzerland

Psychiatric University Hospital ZurichZurich, Switzerland

Universtity Hospital BaselBasel, Switzerland

University Hospital Basel, Clinical Trial UnitBasel, Canton of Basel-City, Switzerland

Private Practice P.GasserSolothurn, Canton of Solothurn, Switzerland

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.